Related references
Note: Only part of the references are listed.1052PDNIVOLUMAB (N) (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH SUNITINIB (S) OR PAZOPANIB (P) IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
A. Amin et al.
ANNALS OF ONCOLOGY (2017)
PD-1/PD-L1 inhibitors
Joel Sunshine et al.
CURRENT OPINION IN PHARMACOLOGY (2015)
Immunotherapy for urothelial cancer: from BCG to checkpoint inhibitors and beyond
Yin Wu et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
David F. McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab for the treatment of cancer
Anasuya Gunturi et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation
Christian U. Blank
CURRENT OPINION IN ONCOLOGY (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
Association between the cytotoxic T-lymphocyte antigen 4+49A/G polymorphism and bladder cancer risk
Lei Wang et al.
TUMOR BIOLOGY (2014)
Cytotoxic T Lymphocyte Antigen-4 Blockade Enhances Antitumor Immunity by Stimulating Melanoma-Specific T-cell Motility
Tsvetelina Pentcheva-Hoang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
The Dual Role of HLA-G in Cancer
Nathalie Rouas-Freiss et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2014)
Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
Jaikumar Duraiswamy et al.
CANCER RESEARCH (2013)
At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Andrew M. Intlekofer et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2013)
B7-H3 is a new cancer-specific endothelial marker in clear cell renal cell carcinoma
Xiaojian Qin et al.
ONCOTARGETS AND THERAPY (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention
Wieger J. Norde et al.
BLOOD (2012)
Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
Daniel S. Chen et al.
CLINICAL CANCER RESEARCH (2012)
HLA-G and HLA-E specific mRNAs connote opposite prognostic significance in renal cell carcinoma
Leos Kren et al.
DIAGNOSTIC PATHOLOGY (2012)
Immunoexpression of B7-H3 in endometrial cancer: Relation to tumor T-cell infiltration and prognosis
Andreas Brunner et al.
GYNECOLOGIC ONCOLOGY (2012)
HLA-G expression is associated with metastasis and poor survival in the Balb/c nu/nu murine tumor model with ovarian cancer
Aifen Lin et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Two Hundred Years of Cancer Research
Vincent T. DeVita et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Immunotherapy of Genitourinary Malignancies
Teruo Inamoto et al.
JOURNAL OF ONCOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Phase 1 Dose-Escalation Trial of Tremelimumab Plus Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Brian I. Rini et al.
CANCER (2011)
Prospects for TIM3-Targeted Antitumor Immunotherapy
Shin Foong Ngiow et al.
CANCER RESEARCH (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Evan J. Lipson et al.
CLINICAL CANCER RESEARCH (2011)
Elusive Identities and Overlapping Phenotypes of Proangiogenic Myeloid Cells in Tumors
Seth B. Coffelt et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Mutational Heterogeneity in Human Cancers: Origin and Consequences
Jesse J. Salk et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2010)
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity
David G. DeNardo et al.
CANCER AND METASTASIS REVIEWS (2010)
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
Bradley C. Carthon et al.
CLINICAL CANCER RESEARCH (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Genomic instability - an evolving hallmark of cancer
Simona Negrini et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Induction of Lymphoidlike Stroma and Immune Escape by Tumors That Express the Chemokine CCL21
Jacqueline D. Shields et al.
SCIENCE (2010)
TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression
Li Yang et al.
TRENDS IN IMMUNOLOGY (2010)
A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
Chrystelle Brignone et al.
CLINICAL CANCER RESEARCH (2009)
Immunotherapy of cancer
Hossein Borghaei et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Suzanne Ostrand-Rosenberg et al.
JOURNAL OF IMMUNOLOGY (2009)
Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma
Paul L. Crispen et al.
CLINICAL CANCER RESEARCH (2008)
The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion
Yih-Wen Chen et al.
CURRENT CANCER DRUG TARGETS (2008)
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
James C. Yang et al.
JOURNAL OF IMMUNOTHERAPY (2007)
Survivin and B7-H1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma
Amy E. Krambeck et al.
CLINICAL CANCER RESEARCH (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
Kimberly E. Beck et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Cytotoxic T-Lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer
JA Blansfield et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
Share Paper
